Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$2.84 CAD
Change Today 0.00 / 0.00%
Volume 0.0
FRX On Other Exchanges
Symbol
Exchange
Toronto
Frankfurt
As of 3:59 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

68 TW Alexander Drive

PO Box 13628

Research Triangle Park, NC 27709

United States

Phone: 919-636-4530

Fax: 919-890-0490

Fennec Pharmaceuticals Inc., a development stage company, operates as a biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. The company’s wholly-owned subsidiary includes Adherex, Inc. Product Candidates Sodium Thiosulfate (STS) is a water soluble thiol compound that acts as a chemical reducing agent that is in two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. Eniluracil (EU) is an oral irreversible dihydropyrimidine dehydrogenase (DPD) inhibitor, the enzyme responsible for rapidly breaking down 5-FU that is completed a Phase II clinical trial in metastatic breast cancer. STS: The company has licensed from Oregon Health & Science University (OHSU) intellectual property rights for the use of STS as a chemoprotectant, and is in the process of developing STS as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children. The company has received Orphan Drug Designation in the United States for the use of STS in the prevention of platinum-induced ototoxicity in pediatric patients. In 2007, the company announced that its collaborative partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial to investigate whether STS reduces hearing loss in children receiving cisplatin, a platinum-based chemotherapy often used in pediatric oncology. In 2008, the company announced the activation of a Phase III trial with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s Oncology Group. Eniluracil: In 2012, the company completed the enrollment of Protocol AHX-03-202, an open-label, randomized Phase II study comparing the completely oral combination of Eniluracil/5-FU/leucovorin to capecitabine monotherapy in metastatic breast cancer. Intellectual Property The company owns 23 issued patents worldwide and has 14 patents pending worldwide. With regard to STS, the company has licensed from Oregon Health and Science University one U.S. and nine foreign patents, with an additional one patent pending. With regard to Eniluracil, the company has been issued 13 patents and is prosecuting 13 additional patents. Research and Development The company’s research and development expenses totaled $0.6 million, as of December 31, 2013. History Fennec Pharmaceuticals Inc. was founded in 1996. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. It was incorporated under the Canada Business Corporations Act in 1996.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRX:CN C$2.84 CAD 0.00

FRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRX.
View Industry Companies
 

Industry Analysis

FRX

Industry Average

Valuation FRX Industry Range
Price/Earnings 19.8x
Price/Sales -- Not Meaningful
Price/Book 29.3x
Price/Cash Flow 20.8x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FENNEC PHARMACEUTICALS INC, please visit www.fennecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.